Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
Primary PBMCs treated with flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 144 hours) secrete more IFN-γ, IL-10, and IL-6 [1]. Using human PBMC or cynomolgus monkeys, flotetuzumab (10-6-102 ng/mL; 24 hours) demonstrated cytotoxicity against the Kasumi-3 AML cell line [1]. Leukemia cell proliferation is dose-dependently inhibited by flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 6 d) [1].
|
---|---|
ln Vivo |
Flotetuzumab (0.5-4 μg/kg; intraperitoneally implanted; continuous infusion for 6 days) showed anti-tumor efficacy in tumor-bearing mice reconstituted with human peripheral blood mononuclear cells (PBMC) [1]. Flotetuzumab (0.5 mg/kg; every 5 days; for 30 days) boosts T cell proliferation and improves mice survival in a mouse NTPL-146 patient-derived acute myeloid leukemia (AML) xenograft (PDX) model and promote T cell proliferation [2].
|
Cell Assay |
Cell viability assay [1]
Cell Types: primary PBMC Tested Concentrations: 0.01 ng/mL, 0.1 ng/mL Incubation Duration: 6 days Experimental Results: Causes dose-dependent depletion of leukemic blast cells, accompanied by expansion and proliferation of autologous T cells The marker Ki-67 was upregulated, and CD8+ cells increased proportionally. |
Animal Protocol |
Animal/Disease Models: PBMCs reconstructed tumor model: NSG/β2m-/- mice were intradermally implanted with KG-1a (AML-M0) cells on day 0, and human PBMCs were injected intraperitoneally (ip) (ip) on day 1.
Doses: 0.5 μg/kg, 1 microgram/kg and 4 microgram/kg; Route of Administration: peritoneal implantation with a mini-osmotic pump; continuous infusion from day 16 to day 22; Experimental Results: significant inhibition of tumor volume. |
References |
[1]. Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015 May 27;7(289):289ra82.
[2]. Barwe SP, et al. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. J Clin Med. 2022 Feb 28;11(5):1333. |
CAS # |
1664355-28-5
|
---|---|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.